AbbVie's tight grip on Humira market raises concerns about biosimilars

[cafead]

via AbbVie’s (ABBV.N) top-selling arthritis drug Humira has held onto more than 80% of patients after facing nine lower-priced rivals in the U.S. in the last year, raising questions about whether the market for prescription biosimilars can survive in its current form, drug pricing experts and analysts say.

article source